Agenus (NASDAQ:AGEN – Get Free Report) announced its earnings results on Tuesday. The biotechnology company reported ($2.04) earnings per share for the quarter, beating the consensus estimate of ($2.36) by $0.32, Zacks reports.
Agenus Stock Down 8.5 %
NASDAQ:AGEN opened at $2.15 on Tuesday. Agenus has a 1-year low of $2.13 and a 1-year high of $19.69. The firm has a market capitalization of $50.44 million, a price-to-earnings ratio of -0.19 and a beta of 1.23. The stock has a fifty day simple moving average of $3.26 and a 200 day simple moving average of $3.88.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research note on Wednesday, January 22nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $10.00.
About Agenus
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
See Also
- Five stocks we like better than Agenus
- What is a support level?
- Top 3 Utilities Stocks Powering Up as Recession Fears Rise
- Business Services Stocks Investing
- Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential
- What Does Downgrade Mean in Investing?
- Costco Price Plunge Equals Opportunity for Investors
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
